Theravance Biopharma TBPH Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Gyre Therapeutics, Inc.GYRE

$1.39M+123%

Rigel PharmaceuticalsRIGL

$636K+39.5%

Zevra Therapeutics, Inc.ZVRA

$626K+19.2%

Aurinia PharmaceuticalsAUPH

$1.71M+62.8%

Mirum Pharmaceuticals, Inc.MIRM

$2.41M+15.6%

Pulmonx CorporationLUNG

$1.24M+12.5%

FAQ

What is Theravance Biopharma's operating lease liabilities (current)?

Theravance Biopharma (TBPH) reported operating lease liabilities (current) of $10.8M in Q2 2026.

How has Theravance Biopharma's operating lease liabilities (current) changed year-over-year?

Theravance Biopharma's operating lease liabilities (current) decreased by 0.9% year-over-year, from $10.9M to $10.8M.

What is the long-term trend for Theravance Biopharma's operating lease liabilities (current)?

Over 5 years (2020 to 2025), Theravance Biopharma's operating lease liabilities (current) has grown at a 2.1% compound annual growth rate (CAGR), from $9.87M to $10.95M.

What does operating lease liabilities (current) mean?

The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.